Hemolytic-Uremic Syndrome
11
3
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
New Analytic Tools for aHUS and C3G Diagnosis
Efficacy of INM004 in Children With STEC-HUS
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
Erythropoietin in Hemolytic Uremic Syndrome
Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion
Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4